QLS-111 ophthalmic solution (0.015%)

DRUG2 trials

Sponsors

Qlaris Bio, Inc.

Conditions

GlaucomaLow-Tension Glaucoma, BilateralLow-Tension Glaucoma, Unspecified EyeNon-proliferative Diabetic Retinopathy (NPDR)Normal Tension Glaucoma (NTG)Open-angle Glaucoma (OAG)

Phase 2

Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)

CompletedNCT06030193

Qlaris Bio, Inc.Glaucoma, Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye +1

Start: 2025-08-13End: 2026-03-23Updated: 2026-04-03

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Active, not recruitingNCT07354477

Qlaris Bio, Inc.Non-proliferative Diabetic Retinopathy (NPDR), Normal Tension Glaucoma (NTG), Open-angle Glaucoma (OAG)

Start: 2026-02-20End: 2026-10-01Target: 14Updated: 2026-09-14